Abstract
Oral timolol taken for the treatment of systemic hypertension has been shown to affect adversely serum lipoprotein levels. In a 15-week study on 19 patients topical timolol therapy for raised intraocular pressure was found to have no significant adverse effect on serum lipoprotein levels. This is reassuring in view of the large number of patients on this form of long term therapy, and selection of the type of beta blocker to use should not be influenced by lipid changes associated with the oral form of the drug.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Affrime M. B., Lowenthal D. T., Tobert J. A., Shirk J., Eidelson B., Cook T., Onesti G. Dynamics and kinetics of ophthalmic timolol. Clin Pharmacol Ther. 1980 Apr;27(4):471–477. doi: 10.1038/clpt.1980.66. [DOI] [PubMed] [Google Scholar]
- Brazier D. J., Smith S. E. Ocular and cardiovascular response to topical carteolol 2% and timolol 0.5% in healthy volunteers. Br J Ophthalmol. 1988 Feb;72(2):101–103. doi: 10.1136/bjo.72.2.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Castelli W. P. The triglyceride issue: a view from Framingham. Am Heart J. 1986 Aug;112(2):432–437. doi: 10.1016/0002-8703(86)90296-6. [DOI] [PubMed] [Google Scholar]
- Fraunfelder F. T., Meyer S. M. Systemic adverse reactions to glaucoma medications. Int Ophthalmol Clin. 1989 Fall;29(3):143–146. doi: 10.1097/00004397-198902930-00002. [DOI] [PubMed] [Google Scholar]
- Gordon T., Castelli W. P., Hjortland M. C., Kannel W. B., Dawber T. R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977 May;62(5):707–714. doi: 10.1016/0002-9343(77)90874-9. [DOI] [PubMed] [Google Scholar]
- Greenberg G., Brennan P. J., Miall W. E. Effects of diuretic and beta-blocker therapy in the Medical Research Council Trial. Am J Med. 1984 Feb 27;76(2A):45–51. doi: 10.1016/0002-9343(84)90956-2. [DOI] [PubMed] [Google Scholar]
- Helgeland A., Hjermann I., Leren P., Enger S., Holme I. High-density lipoprotein cholesterol and antihypertensive drugs: the Oslo study. Br Med J. 1978 Aug 5;2(6134):403–403. doi: 10.1136/bmj.2.6134.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Houston M. C. New insights and new approaches for the treatment of essential hypertension: selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertension. Am Heart J. 1989 Apr;117(4):911–951. doi: 10.1016/0002-8703(89)90631-5. [DOI] [PubMed] [Google Scholar]
- Leren P., Foss P. O., Nordvik B., Fossbakk B. The effect of enalapril and timolol on blood lipids. A randomized multicenter hypertension study in general practice in Norway. Acta Med Scand. 1988;223(4):321–326. doi: 10.1111/j.0954-6820.1988.tb15880.x. [DOI] [PubMed] [Google Scholar]
- Miller G. J., Miller N. E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975 Jan 4;1(7897):16–19. doi: 10.1016/s0140-6736(75)92376-4. [DOI] [PubMed] [Google Scholar]
- Passo M. S., Palmer E. A., Van Buskirk E. M. Plasma timolol in glaucoma patients. Ophthalmology. 1984 Nov;91(11):1361–1363. doi: 10.1016/s0161-6420(84)34141-0. [DOI] [PubMed] [Google Scholar]
- Pocock S. J., Shaper A. G., Phillips A. N. Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. BMJ. 1989 Apr 15;298(6679):998–1002. doi: 10.1136/bmj.298.6679.998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weidmann P., Uehlinger D. E., Gerber A. Antihypertensive treatment and serum lipoproteins. J Hypertens. 1985 Aug;3(4):297–306. doi: 10.1097/00004872-198508000-00001. [DOI] [PubMed] [Google Scholar]